What This Top Dividend Portfolio Is Holding Now: Royal Dutch Shell Plc, GlaxoSmithKline plc and HSBC Holdings plc

Royal Dutch Shell Plc (LON:RDSB), GlaxoSmithKline plc (LON:GSK) and HSBC Holdings plc (LON:HSBA) are the heavyweight holdings of Merchants Trust (LON:MRCH).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

HSBC

Merchants Trust (LSE: MRCH) is on track to deliver 31 straight years of dividend increases.  The prospective yield is 4.6% at a recent share price of 516p. Picking great dividend shares has helped Merchants outperform the FTSE All-Share Index over the past three, five and 10 years.

Let’s take a look at the trust’s current top three holdings: Royal Dutch Shell (LSE: RDSB), GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and HSBC (LSE: HSBA).

Royal Dutch Shell

The shares of oil titan Royal Dutch Shell are trading close to a 52-week high, having put on a bit of a spurt since the company announced its annual results on 30 January.

New boss Ben van Beurden, said that after Shell’s heavy investment for growth in recent years, “2014 will be a year where we are changing emphasis, to improve our returns and cash flow performance”. The new focus is good news for shareholders’ dividends.

The board raised the 2013 payout (declared in US dollars) by 4.7%, and early indications suggest a rise of 4.4% for 2014. The consensus forecast for the sterling dividend is 114p, giving a prospective income of 4.8% at a recent share price of 2,365p — well ahead of the market average yield of 3.1%.

GlaxoSmithKline

Pharmaceuticals group GlaxoSmithKline (GSK) is another global giant currently offering a dividend yield well above the market average.

GSK reported core earnings-per-share (EPS) growth of 4% on turnover growth of 1% when announcing its annual results earlier this month. The board guided for accelerating growth in 2014, saying it expects turnover to rise by 2% and EPS by 4%-8%.

The company increased the 2013 dividend by 5.4%, and analysts are forecasting a 5.1% rise to 82p this year. That represents a prospective yield of 4.9% at a recent share price of 1,680p.

HSBC

Concerns about slowing growth in many emerging markets have weighed on companies with high exposure to these economies. The shares of HSBC (originally the Hong Kong and Shanghai Banking Company), with its big presence in Asia, are currently trading close to a 52-week low.

The company posted a 9% rise in profits for 2013 in results announced this week, but that fell a bit short of market expectations. However, chief executive Stuart Gulliver said three years of restructuring and cost-cutting had made the group “leaner and simpler … with strong potential for growth”. The board upped the dividend (declared in US dollars) by 8.9%, with the chief exec saying: “Strong capital generation continues to support our progressive dividend policy”.

HSBC has said it intends to maintain the first three quarterly dividends for this year at the same level as 2013. Even a de minimis increase in the final dividend, to maintain the progressive dividend policy, would see a $0.50 payout for the year — about 31p at current exchange rates, giving a prospective income of around 5% at a recent share price of 628p

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> G A Chester does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

UK shares: a once-in-a-decade chance to bag sky-high passive income

The FTSE 250 is offering up incredible passive income opportunities right now. Our writer takes a look at one stock…

Read more »

Investing Articles

2 dirt cheap FTSE 100 and FTSE 250 growth shares to consider!

Looking for great growth and value shares right now? These FTSE 100 and FTSE 250 shares could offer the best…

Read more »

Investing Articles

No savings? I’d use the Warren Buffett method to target big passive income

This Fool looks at a couple of key elements of Warren Buffett's investing philosophy that he thinks can help him…

Read more »

Investing Articles

This FTSE 100 hidden gem is quietly taking things to the next level

After making it to the FTSE 100 index last year, Howden Joinery Group looks to be setting its sights on…

Read more »

Investing Articles

A £20k Stocks and Shares ISA put into a FTSE 250 tracker 10 years ago could be worth this much now

The idea of a Stocks and Shares ISA can scare a lot of people away. But here's a way to…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

What next for the Lloyds share price, after a 25% climb in 2024?

First-half results didn't do much to help the Lloyds Bank share price. What might the rest of the year and…

Read more »

Investing Articles

I’ve got my eye on this FTSE 250 company

The FTSE 250's full of opportunities for investors willing to do the search legwork, and I think I've found one…

Read more »

Investing Articles

This FTSE 250 stock has smashed Nvidia shares in 2024. Is it still worth me buying?

Flying under most investors' radars, this FTSE 250 stock has even outperformed the US chip maker year-to-date. Where will its…

Read more »